

|   |            |                         |
|---|------------|-------------------------|
| <b>Patient:</b>   | Client:    | ARUP Test Code: 3000147 |
| DOB:                      Age:                      Gender: |            |                         |
| <b>Patient Identifiers:</b>                                 | Physician: | Collection Date:        |
| <b>Visit Number (FIN):</b>                                  |            | Received in lab:        |
|   |            | Completion Date:        |

This is an interim report for an integrated screening test panel. The first sample was processed and all required first trimester information has been received. The MoMs, risks, and screening results will be reported after we receive and process the second trimester sample.

Second trimester serum markers are needed to provide a final interpretation. The ideal time to draw the second sample is between 16 and 18 weeks gestation. For this patient, ideally collect between 05-21-21 and 06-04-21. However, the sample may be drawn as early as 05-07-21 or as late as 07-22-21 and still provide valid information.

Gestational Age Comment:

Section 79-1 of New York State Civil Rights Law requires informed consent be obtained from patients (or their legal guardians) prior to pursuing genetic testing. These forms must be kept on file by the ordering physician. Consent forms for genetic testing are available at [www.aruplab.com](http://www.aruplab.com). Incidental findings are not reported unless clinically significant but are available upon request.

PAPP-A Maternal Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Maternal Screen Interpretation Compliance Statement: This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

| <b>Patient Information Used in Risk Calculations:</b> |                | <b>Marker</b> | <b>Measurement</b> |
|---|----------------|---------------|--------------------|
| Maternal Age at Delivery:                             | 23.0 yr        | PAPP-A        | 2274.1 ng/mL       |
| Maternal Weight:                                      | 150.0 lbs.     | NT            | 1.00 mm            |
| Estimated Due Date:                                   | 11-05-21       |               |                    |
| Gestational Age at Draw:                              | 12 wks, 6 days |               |                    |
| Number of Fetuses:                                    | Singleton      |               |                    |



Patient: ARUP Accession: 21-119-154373

# Maternal Serum Screening, Integrated, Specimen #1, PAPP-A, NT

Patient: | Date of Birth: | Gender: | Physician:  
Patient Identifiers: | Visit Number (FIN):

Maternal Race: Nonblack  
Current Smoker: No  
Family History of Aneuploidy: No  
Specimen: Initial sample  
Crown Rump Length: 67.5 mm  
Crown Rump Length (Twin B): Not Applicable  
Sonographer Certification #:  
Sonographer Name:  
Ultrasound Date: 04-29-21  
Best Date to Draw Sample #2 By: 06-04-21

## Reference Information

The following links or information offer complete and up to date information about this test, including access to ARUP Consult™ disease topics and other supplemental resources.

- [Maternal Serum Screening, Integrated, Specimen #1, PAPP-A, NT](http://ltd.aruplab.com/tests/pub/3000147)  
(http://ltd.aruplab.com/tests/pub/3000147)
- [Prenatal Aneuploidy Screening](https://www.aruplab.com/genetics/tests/prenatal)  
(https://www.aruplab.com/genetics/tests/prenatal)
- [Additional Technical Information](http://ltd.aruplab.com/Tests/Pdf/311)  
(http://ltd.aruplab.com/Tests/Pdf/311)



Patient:

ARUP Accession: 21-119-154373